9. Glioma

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Ross Pinkerton

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch9

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Pinkerton, R. (2013) Glioma, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch9

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. Royal Children's Hospital, Brisbane, QLD, Australia

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309

SEARCH

Keywords:

  • central nervous system tumors;
  • chemotherapy;
  • children;
  • glioma;
  • radiation therapy

Summary

Gliomas constitute over 50% of central nervous system tumors in children, and most are low grade. The reports cited in this chapter are specifically related to either supratentorial and cerebellar high-grade gliomas or diffuse intrinsic pontine gliomas (DIPG). Historically, the prognosis of children with high-grade glioma has been poor. The prognosis appears to have decreased since the Children's Cancer Group (CCG)-943 study that compared the addition of chemotherapy with lomustine and vincristine to radiation therapy alone. This study helped establish surgery, radiation, and chemotherapy as the standard approach for these tumors in children. The treatment of pediatric high-grade glioma continues to be a dilemma. The number of reported trials in childhood glioma is limited and their results are of insufficient power to provide unequivocal evidence-based outcomes for clear diagnostic, prognostic, and therapeutic directions. More well-co-ordinated trials incorporating biological correlations are needed.